Intravitreal Ranibizumab and/or Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion

Purpose: To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central or branch retinal vein occlusion (CRVO or BRVO) in a clinical setting. Methods: Retrospective analysis of consecutive patients followed for at least 6 months. Data recorded included the type of occlusion, initial and final visual acuity, and number of injections. Results: Sixty-five patients were included, 26 had CRVO and 39 BRVO. Mean (+/-SD) follow-up duration was 16 (+/-7.7) months. Twenty-four (36.9%) patients received ranibizumab in monotherapy, 19 patients (29.3%) dexamethasone in monotherapy, and 22 patients (33.8%) received successively both treatments. In dexamethasone-treated patients, mean (+/-SD) visual acuity gain was 5.8 +/- 10.7 letters for BRVO and 16.8 +/- 15.6 letters for CRVO. In ranibizumab-treated patients, mean (+/-SD) visual acuity gain was 9.2+/-10 letters for BRVO and 18.2+/-20.5 letters for CRVO. Conclusion: Both intravitreal ranibizunnab and dexamethasone intravitreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion. (C) 2014 S. Karger AG, Basel